Sign in
Taking people in United StatesPhase 2

Allocetra injections into the joint for knee osteoarthritis compared with placebo

Tests Allocetra injected into the knee in people with painful knee osteoarthritis.

Key facts

Who runs it
Enlivex Therapeutics Ltd.
Where
Longwood, Miami, New Orleans, and Troy, United StatesSee the 4 sitesAlso in 2 other countries, 13 sites
Trial code
Registry title
Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
Status
Recruiting
Phase
Phase 2
People taking part
182 people, planned
Started
1 May 2026
Expected to end
Apr 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Allocetra
  • Placebo
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 64 or older with moderate-to-severe primary knee osteoarthritis (wear-and-tear arthritis) that causes symptoms. Participants get three knee injections of Allocetra or placebo.

Age
64 years or older
Sex
All sexes. Women must be postmenopausal (at least 12 months without periods) or surgically sterilized.
Disease stage
Primary femorotibial knee osteoarthritis, Kellgren-Lawrence grade 2 or 3 on X-ray in the studied knee, with knee pain after stopping pain medicines.
Earlier treatment
At least 2 osteoarthritis treatments that did not work well enough or could not be tolerated.

Main reasons for not taking part

  • Severe or end-stage osteoarthritis, or major structural problems or instability of the studied knee
  • Recent major injury, surgery or joint injection in the studied knee, or past infection or tumor there
  • Inflammatory joint disease or crystal-deposit disease (such as gout)
  • Immune-suppressing treatment, weak immune system, active infection, or BMI over 40 kg/m²
  • Known blood clotting problem or use of blood thinners or anti-platelet medicines

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Participants must meet all of the inclusion criteria listed below to be eligible for the study:
  • Age 64 years or above
  • Diagnosis of primary femorotibial knee OA
  • Radiographic evidence of knee OA defined as Kellgren-Lawrence (KL) grade 2 or 3 in the index knee
  • Participants who are intolerant to, or have failed to adequately respond to at least 2 OA therapies
  • Index knee pain assessed during the screening period and following wash-out of pain medications
  • Willingness to abstain from prohibited medications/treatments during the trial
  • Women who are postmenopausal (≥12 months natural amenorrhea without alternative cause) or surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)
  • Male participants with partners of childbearing potential, who are not surgically sterile (vasectomy) for at least 6 months prior to randomization, must use condoms with spermicide in addition to their partner's contraception from randomization and for 90 days after last dose

Who cannot take part

  • Recent major injury, surgical procedure, or intra-articular treatment in the index knee
  • Use of medications that may interfere with pain assessment or study outcomes
  • Known coagulopathy or use of anticoagulant/antiaggregant medication
  • Any known history of infection or tumor of the index knee, or active infection at the intended injection site
  • Any known history of inflammatory arthropathy or crystal-deposition disease
  • Any severe systemic cartilage, bone, or musculoskeletal disorder that may interfere with study outcomes
  • Clinically significant widespread pain syndromes
  • Immunosuppressive therapy, clinically significant immunodeficiency, or active infection
  • Significant uncontrolled systemic disease or clinically significant findings on screening laboratory tests or physical examination
  • Participants will be excluded from the study if they meet any of the following criteria:
  • Severe or end-stage osteoarthritis of the index knee
  • Clinically significant structural abnormalities or instability of the index knee
  • Body Mass Index (BMI) >40 kg/m²

Where in United States

Also in 2 other countries, 13 sites

  • Future Medical ResearchLongwood, United StatesContact: Mayra Abreu, MDTaking people
  • South Florida Research Phase I-IVMiami, United StatesContact: Eduardo Viera, MDTaking people
  • Delricht Research-Touro Medical CenterNew Orleans, United StatesContact: Patrick Dennis, MDTaking people
  • Oakland Medical ResearchTroy, United StatesContact: Jay Sandberg, MDTaking people

About the trial

What the trial wants to find out

This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).

The 2 groups in the trial

  • AllocetraTreatment being tested

    Three intra-articular injections of Allocetra at a selected dose, into the index knee.

  • PlaceboPlacebo, for comparison

    Three intra-articular injections of placebo into the index knee.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
Plain-language title
Allocetra injections into the joint for knee osteoarthritis compared with placeboGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 October 2026